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Abstract.
Multiple studies have implicated the depletion of isoprenoid biosynthetic pathway intermediates in induction of autophagy. However, the exact mechanism by which isoprenoid biosynthesis inhibitors induce autophagy has not been well established. We hypothesized that inhibition of farnesyl diphosphate synthase (FDPS) and geranylgeranyl diphosphate synthase (GGDPS) by bisphosphonates would induce autophagy by depleting cellular geranylgeranyl diphosphate (GGPP) and impairing protein geranylgeranylation. We show herein that an inhibitor of FDPS (zoledronate) and an inhibitor of GGDPS (digeranyl bisphosphonate, DGBP) induce autophagy in PC3 prostate cancer and MDA-MB-231 breast cancer cells as measured by accumulation of the autophagic marker LC3-II. Treatment of cells with lysosomal protease inhibitors (E64d and pepstatin A) in combination with zoledronate or digeranyl bisphosphonate further enhances the formation of LC3-II, indicating that these compounds induce autophagic flux. Importantly, the addition of exogenous GGPP prevented the accumulation of LC3-II and impairment of Rab6 (a GGTase II substrate) geranylgeranylation by isoprenoid pathway inhibitors (lovastatin, zoledronate, and DGBP). However, exogenous GGPP did not restore isoprenoid pathway inhibitorinduced impairment of Rap1a (a GGTase I substrate) geranylgeranylation. In addition, specific inhibitors of farnesyl transferase and geranylgeranyl transferase I are unable to induce autophagy in our system. Furthermore, the addition of bafilomycin A1 (an inhibitor of autophagy processing) enhanced the anti-proliferative effects of digeranyl bisphosphonate. These results are the first to demonstrate that bisphosphonates induce autophagy. Our study suggests that induction of autophagy in PC3 cells with these JPET #175521 4 agents is likely dependent upon impairment of geranylgeranylation of GGTase II substrates.
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Introduction.
The isoprenoid biosynthetic pathway ( Fig. 1) is responsible for the production of a wide array of compounds with diverse biological functions. Small molecule inhibitors of this pathway have yielded clinical success. The statins (e.g. lovastatin) are commonly prescribed for hypercholesterolemia and inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (Endo et al., 1976) , which is the rate-limiting step of cholesterol biosynthesis (Siperstein and Fagan, 1966) . The nitrogenous bisphosphonates (e.g. zoledronate) target farnesyl diphosphate synthase (FDPS) (van Beek et al., 1999) and are used for bone-related disorders such as osteoporosis.
While statins and nitrogenous bisphosphonates are used for distinct clinical disorders, they have common effects within cells, including depletion of pathway intermediates farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP). FPP is at the major branch point of the pathway, being used in the synthesis of cholesterol or GGPP as well as other molecules. Farnesyl and geranylgeranyl moieties can be posttranslationally adducted onto select proteins in processes termed farnesylation and geranylgeranylation (collectively referred to as prenylation), respectively (Zhang and Casey, 1996) . Farnesylation is catalyzed by farnesyl transferase (FTase), while geranylgeranylation can be catalyzed by either geranylgeranyl transferase (GGTase) I or GGTase II (also referred to as Rab GGTase), depending upon the nature of the acceptor protein. For proteins that are farnesylated or geranylgeranylated, such as small GTPases of the Ras and Rho family, prenylation is essential for proper localization and function (Swanson and Hohl, 2006) . This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on February 18, 2011 as DOI: 10.1124 at ASPET Journals on April 5, 2017 jpet.aspetjournals.org Downloaded from JPET #175521 6 Macroautophagy (hereafter referred to as autophagy) is a cellular process which degrades damaged cytoplasmic organelles as well as long-lived, misfolded, or aggregated proteins (Glick et al., 2010) . During autophagy, a target substrate is first encapsulated in a double membrane vesicle known as an autophagosome. Autophagosomes can then fuse with lysosomes to form autolysosomes, where the contents are degraded. This process ultimately allows for the recycling of amino acids and other degraded products and is upregulated in response to cellular stresses such as starvation.
Inhibitors of the isoprenoid biosynthetic pathway have been linked to autophagy.
Studies have shown that statins are capable of inducing autophagy in A204 human rhabdomyosarcoma cells (Araki and Motojima, 2008) . More recently, statins have been shown to induce autophagy in PC3 prostate cancer cells, and the induction of autophagy was prevented by the addition of the geranylgeraniol (GGOH), the alcohol form of GGPP (Parikh et al., 2010) . It remains uncertain whether this prevention is due to restoration of isoprenoid levels or protein prenylation. In addition, a novel GGTase I/II inhibitor when combined with a statin induced autophagy in the STS-26T malignant peripheral nerve sheath tumor cell line (Sane et al., 2010) , suggesting that the impairment of prenylation can induce autophagy. However, this drug combination does not allow for the distinction of whether the impairment of GGTase I or GGTase II substrate geranylgeranylation is responsible for autophagic induction. Further complicating the interrelationship of prenylation and autophagy, farnesyl transferase inhibitors have been shown to induce autophagy in Panc-1 pancreatic cancer and U2OS osteosarcoma cells (Pan et al., 2008) .
In addition, an inhibitor of isoprenylcysteine carboxyl methyltransferase, an enzyme required in later steps of prenylation processing, induced autophagy in PC3 and HepG2
This article has not been copyedited and formatted. The final version may differ from this version. (Wang et al., 2008; Wang et al., 2010) . A yeast deletion collection was treated with nitrogenous bisphosphonates, which identified ATG4, ATG11, ATG14 and ATG16 (all autophagy related genes) hemizygous strains as having increased sensitivity to nitrogenous bisphosphonates (Bivi et al., 2009 ).
Our collaborators have synthesized digeranyl bisphosphonate (DGBP) and we have shown it to specifically inhibit geranylgeranyl diphosphate synthase (GGDPS) (Shull et al., 2006; Wiemer et al., 2007) . This compound specifically impairs protein geranylgeranylation via depletion of GGPP in various cell types. Furthermore, GGPP depletion results in the inhibition of cancer cell migration (Dudakovic et al., 2010) and induction of apoptosis (Dudakovic et al., 2008) . We hypothesize and provide evidence herein to support that depletion of GGPP by bisphosphonate inhibitors of FDPS (i.e. Triton X-114 separation. Based on the method of Bordier (Bordier, 1981) . For separation of prenylated and unprenylated Rab6, cells were lysed in ice cold TX114 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-114). Cell lysate was passed through a 27 gauge needle and cleared by centrifugation at 12,000 x g for 15 minutes at 4°C, after which the supernatant was transferred to a new tube and incubated at 37°C for 10 minutes and then spun down at room temperature at 12,000 x g for 2 minutes. The aqueous (upper) phase was transferred to a new tube, and the lower detergent phase was diluted into buffer without Triton X-114 prior to electrophoresis.
Western Blot Analysis. Protein concentrations were determined by the bicinchoninic acid method. Proteins were resolved on 12 or 15% gels and transferred to polyvinylidene difluoride membranes by electrophoresis. After blocking in 5% non-fat dry milk for 45 minutes, primary and secondary antibodies were added sequentially for 1 hour at 37 o C and proteins visualized using an ECL detection kit.
MTT Assay. 8 x 10 4 cells per well were allowed to adhere in 24-well plates overnight. presence of isoprenoid biosynthetic pathway inhibitors, MTT assay was performed at 48 hours (Fig. 2B) . Additionally, cell proliferation was assessed by 3 H-thymidine incorporation assay (Fig. 2C) . Concentration-dependent reduction in MTT activity and inhibition of DNA synthesis ( 3 H-thymidine incorporation assay) are observed with all three inhibitors. Lovastatin is most potent while zoledronate is least potent at decreasing MTT activity and DNA synthesis.
Bisphosphonates induce LC3-II accumulation in PC3 cells. To establish if
bisphosphonates induce LC3-II accumulation, PC3 cells were treated with lovastatin, zoledronate, and DGBP for 24 and 48 hours (Fig. 3A) . As previously described, statins have been shown to induce autophagy in PC3 cells (Parikh et al., 2010) . Thus, lovastatin is used as a positive control for induction of autophagy. To assess LC3-II protein levels, an antibody was used that specifically detects the LC3-II form of LC3 is used in our studies. The appearance of the LC3-II band on the western blot is an established method for the detection of autophagy (Glick et al., 2010; Mizushima and Yoshimori, 2007) .
LC3-II accumulation is not apparent at 24 hours with the use of isoprenoid pathway inhibitors. In contrast, LC3-II accumulation is observed at 48 hours with the use of the positive control (lovastatin) and bisphosphonates (zoledronate and DGBP). The appearance of LC3-II is detectable at 10 µM DGBP and 50 µM zoledronate, and this effect is concentration-responsive with respect to both drugs. Protein prenylation status was also assessed as described previously (Fig 3A) . In addition, we utilized Rab6 to evaluate the status of proteins geranylgeranylated by GGTase II (Fig. 3B) . In order to assess Rab6's prenylation status, cells were lysed in Triton X-114, which can undergo a 13 from hydrophilic (aqueous phase) proteins (Bordier, 1981) . The detergent-rich fraction retains prenylated proteins, while unprenylated proteins are found in the aqueous phase (Ren et al., 1997) ; thus impairment of Rab6 geranylgeranylation in noted by the appearance of a band in the aqueous fraction of the western blots for Rab6. At 24 and 48 hours, the inhibition of Rab6 processing is noted with all isoprenoid pathway inhibitors.
Bisphosphonate-induced LC3-II accumulation is dependent on GGPP depletion in PC3 cells. In order to determine if the effects of bisphosphonates on LC3-II accumulation are dependent on the depletion of specific molecules within the isoprenoid pathway, inhibitors were co-administered with exogenous isoprenoid pathway intermediates for 48 hours (Fig. 3C ). The addition of mevalonate and GGPP, but not FPP completely prevents the effects of lovastatin on the induction of autophagy as measured by LC3-II levels. FPP addition alone does not prevent lovastatin's effects because of the lack of isopentenyl diphosphate (IPP) to generate GGPP from FPP (Fig. 1) . Similarly, GGPP, but not FPP, completely prevents LC3-II accumulation by zoledronate. GGPP also entirely prevents the effects of DGBP on LC3-II accumulation. Notably, isoprenoid pathway inhibitor-induced impairment of Rap1a (a GGTase I substrate) geranylgeranylation was not prevented by GGPP addition under the conditions tested;
while isoprenoid pathway inhibitor-induced impairment of Rab6 (a GGTase II substrate) geranylgeranylation was completely prevented by GGPP addition (Fig. 3D) .
Bisphosphonates induce autophagic flux in PC3 cells. The accumulation of LC3-II
can be caused by induction of autophagy as well as by inhibition of autophagosomal processing (Mizushima and Yoshimori, 2007) . In order to confirm that GGPP depletion by bisphosphonates genuinely induces autophagy, experiments were performed to This article has not been copyedited and formatted. The final version may differ from this version. Of note, higher concentrations of zoledronate and DGBP were also unable to induce LC3-II accumulation in these two cell lines (data not shown). H-thymidine incorporation at 48 hours (Fig. 7) . Bafilomycin A1
Inhibition of either FTase or
is an inhibitor of fusion between autophagosomes and lysosomes. The combination of zoledronate and bafilomycin A1 did not significantly decrease MTT activity (Fig. 7A ), or DNA synthesis (Fig. 7B ) when compared to single agents. In contrast, the combination of DGBP and bafilomycin A1 significantly decreased MTT activity (Fig. 7A ) and DNA synthesis ( Fig. 7B ) when compared to each individual agent.
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Discussion.
It is well established that statins and nitrogenous bisphosphonates deplete isoprenoid pathway intermediates (Wiemer et al., 2009 ). Many of the cellular effects of these agents have been attributed to the depletion of GGPP (Coxon et al., 2004; Xia et al., 2001 ). Our prior work further explored cellular consequences of GGPP depletion through the utilization of a novel bisphosphonate that directly inhibits GGDPS (Dudakovic et al., 2008; Dudakovic et al., 2010) . Other recent work has suggested that statins can induce autophagy (Parikh et al., 2010) . In this study, we explore the possibility that more specific depletion of GGPP by bisphosphonates would induce autophagy in PC3 prostate cancer cells.
We have shown for the first time that bisphosphonate inhibitors of FDPS (i.e. STS-26T MPNST cells (Sane et al., 2010) . These other results may be a consequence of this novel GGTI inhibiting both GGTase I and II. A recent study using the STS-26T
human malignant peripheral nerve sheath tumor cell line found that the combination of an FTI and lovastatin (which also resulted in inhibition of Rab geranylgeranylation) caused the formation of LC-II but did not increase autophagic flux, which the authors suggest resulted in an abortive autophagic program and non-apoptotic cell death (Wojtkowiak et al., 2011) . We did not detect apoptosis as measured by PARP cleavage in PC3 cells (data not shown); however, we did not directly measure cell death to determine if nonapoptotic cell death occurred. Specific impairment of geranylgeranylation of GGTase II substrates may be a mechanism by which GGPP depletion causes LC3-II accumulation.
However, the lack of commercially available reagents does not allow for direct examination of this hypothesis at this time. Previous studies have shown that farnesyl transferase inhibitors can induce autophagy (Pan et al., 2008) . Our results did not show accumulation of LC3-II due to FTI-277 treatment in PC3 cells. Pan et al. speculate that the inhibition of Rheb farnesylation by FTIs is responsible for autophagy induction (Pan et al., 2009) . The difference between our and their data is likely attributable to differences in cell lines, as our own data show results dependent upon cell line usage.
Furthermore, we speculate that PC3 cells may be dysfunctional in the Rheb-mTOR arm of the autophagic pathway because in addition to a lack of FTI-induced autophagy, we also did not detect LC3-II accumulation upon treatment with rapamycin (data not shown).
Rapamycin is an mTOR inhibitor that can induce autophagy.
Nitrogenous bisphosphonates are currently used for treatment of bone-related metastatic cancers (Licata, 2005 in the presence or absence of lysosomal protease inhibitors (10 µg/ml Pepstatin A and 10 µg/ml E64-d) for 48 hours. Cell lysis was followed by western blotting to assess LC3-II protein levels. 
